Maintain pressure on reforms to protect NHSBipolar drug nears approval
The European Medicines Agency (EMEA) has issued a positive opinion on a Marketing Authorisation Application for aripiprazole in treating patients who experience predominantly manic episodes and whose manic episodes respond to the drug. Its developers expect a final decision on the marketing authorisation in April 2008.
Aripiprazole received approval for the treatment of schizophrenia in 2004. If approved, aripiprazole will be only the second atypical antipsychotic indicated for the prevention and treatment of manic episodes in the past five years.
Online training units, written and reviewed by experts. Earn two hours' CPD and a personalised certificate for your portfolio.
Subscribers get five FREE learning units and non-subscribers can access each learning unit for £10 + VAT.
Share
Have your say
You must sign in to make a comment.